RSS

safety study

UK-based biotechnology company, ReViral, has announced top-line safety and pharmacokinetic (PK) data from the Phase I single and multiple ascending dose (SAD and MAD) trial of RV521. more

News

Ablynx has completed target enrolment of a phase I/IIa safety study of its anti-RSV nanobody, ALX-0171 for the treatment of respiratory syncytial virus (RSV) infection in infants more

News